In patients with breast cancer YKL-39 was exclusively expressed in TAMs in tumor mass, and elevated levels of YKL-39 in primary tumors significantly correlated with metastatic relapse after therapy onset (6). This evidence concerns the gene CHI3L2 and neoplasm.